I Feel Like I ’m Burning Alive. It ’ s Hard for People to Believe Me
In 2018, I woke up on my birthday around 2 or 3 a.m. with a funny feeling in my left hand. It started as a slight itch on my thumb that quickly morphed into a different sensation—the feeling of the thumb beginning to swell, followed by the same feeling in my fingers and sections of my palm, until my hand was almost double its normal size. Later that morning, I visited an orthopedist I’d seen once or twice before for other reasons. He gave me a shot to prevent further swelling, and I went on my way. It was an unremarkable visit. Soon after, another strange thing happened: My hands began to feel like they were on...
Source: TIME: Health - February 24, 2023 Category: Consumer Health News Authors: Je Banach Tags: Uncategorized Evergreen freelance health Source Type: news
Evidence Found of Causal Link for Multisite Chronic Pain and MS, RA
WEDNESDAY, Feb. 22, 2023 -- Multisite chronic pain is causally associated with a higher risk for multiple sclerosis (MS) and rheumatoid arthritis (RA), but not with other autoimmune diseases (AIDs), according to a study published online Feb. 9 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2023 Category: Pharmaceuticals Source Type: news
Travere Therapeutics drug approved for rare kidney disease - STAT
SAN DIEGO — Travere Therapeutics, a biotech focused both on treating rare diseases and distancing itself from controversial founder Martin Shkreli, on Friday won accelerated approval for a drug that treats IgA nephropathy, a rare and deadly autoimmune disease that attacks the kidneys and can lead…#san #martinshkreli #iga #filspari #phase3 (Source: Reuters: Health)
Source: Reuters: Health - February 18, 2023 Category: Consumer Health News Source Type: news
UCLA receives $20-million gift to establish center for study of microbial organisms
Andrea and Donald Goodman, and Renee and Meyer Luskin, donated the money for the UCLA Goodman-Luskin Microbiome Center to develop treatments for autoimmune diseases. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - February 16, 2023 Category: Science Authors: Christian Martinez Source Type: news
UCLA receives $20 million to establish Goodman –Luskin Microbiome Center
Key takeawaysA $20 million gift from Andrea and Donald Goodman and Renee and Meyer Luskin will fund a new center at UCLA focused on the microbiome and its effect on health.Investigators at the new center will study the microbiome’s role in disease prevention and the body’s immune response.The enterprise will be led by Elaine Hsiao, UCLA ’s De Logi Professor of Biological Sciences.Among the most promising areas of scientific inquiry is the study of the human microbiome and its effect on health. To fuel more rapid progress in this field, Andrea and Donald Goodman and Renee and Meyer Luskin have made a $20 million g...
Source: UCLA Newsroom: Health Sciences - February 15, 2023 Category: Universities & Medical Training Source Type: news
Health Plans Get Very Poor Scores for Access to Autoimmune Drugs Health Plans Get Very Poor Scores for Access to Autoimmune Drugs
Three out of four insurance plans use policies that result in significant to severe restriction of access to medications for seven autoimmune diseases, according to the analysis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 14, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Why It ’ s So Hard to Have Your Fertility Tested
Patients often say the same thing in appointments with Dr. Abey Eapen, an infertility specialist at UT Southwestern Medical Center: “I never learned about this in my high school.”
For many couples, having a baby is far more difficult than it was made out to be in sex ed. While many women in heterosexual couples get pregnant within a few months of trying, studies suggest up to 15% of couples are unable to conceive after a year of having unprotected sex. That means they meet the clinical definition of infertility: not conceiving within a year if the woman is younger than 35, or within six months if she’s 35...
Source: TIME: Health - February 9, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate medicine Wellbeing Source Type: news
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
SPRING HOUSE, PENNSYLVANIA, February 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition which can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and their fetus are incompatible.1 The trial met the primary endpoint, with the majority of pregnant patients who received nipocalimab achieving a live b...
Source: Johnson and Johnson - February 8, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Autoimmune diseases and women ’s health spotlighted during webinar
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2022/2/community-impact/autoimmune-diseases/thumb931016.jpg?itok=XxAzkdWt" /><br /><p>Members of the NIEHS Women's Health Awareness community learned how conditions such as lupus can affect pregnancy, during Jan. 13 event.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Fred Miller retires from NIEHS Clinical Research Branch
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2021/4/awards-recognition/fred-miller/thumb911673.jpg?itok=mE-ZW-j4" /><br /><p>During the past 40 years, he and his team have made some of the most groundbreaking discoveries in the study of autoimmune disease.</p> (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Measuring autoimmunity in America
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2018/4/science-highlights/autoimmunity/thumb842781.jpg?itok=_rOnOMOL" /><br /><p>NIEHS clinical researcher Fred Miller discussed the increase in autoimmune diseases in the U.S., and the research to better understand why.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
Capitol Hill briefing — autoimmune disease and environmental exposure
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2017/11/community-impact/autoimmune/thumb833390.jpg?itok=PuOu-7oM" /><br /><p>A congressional briefing focused on the connections between autoimmune disease and genetic and environmental factors.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
Biotech Precigen raises $75M to advance treatments for rare diseases
Precigen Inc. (NASDAQ: PGEN) has raised $75 million in a public offering that closed Friday and intends to use the proceeds to speed development of its experimental treatments for multiple rare diseases.
The clinical-stage biotech, which is developing gene and cell therapies for cancers, autoimmune disorders and infectious diseases, sold 42.86 million shares of common stock for $1.75 each. The company also gave the underwriters an option to buy up to 6.43 million additional shares in the 30 days … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 1, 2023 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news
